Press Release: Nocion : Nocion Therapeutics Announces First Patient Dosed in ASPIRE Phase 2b Chronic Cough Study

WATERTOWN, Mass.--(BUSINESS WIRE)--Nocion Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel small molecule charged sodium channel blockers called "nocions", that selectively silence actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain, today announced that the first patient has been dosed in the Phase 2b ASPIRE clinical trial of taplucainium for the treatment of chronic cough. ASPIRE is a Phase 2b, randomized, double-b